When the UNC Center for Gastrointestinal Biology and Disease was initially established it emphasized analysis of epithelial transport, growth, development, and repair, including control of these functions by subepithelial immune and mesenchymal cells. From the outset, it was recognized that a Core Facility capable of measuring levels of soluble signaling molecules (such as peptide hormones, growth factors, eicosanoids, cytokines, and cyclic nucleotides) would be essential to investigators pursuing these goals. For this reason, an Immunoassay (IA) Core was established, and staffed with a Core Director (Dr. Don Powell) and a Core Technician. In 1991, Dr. Michael Goy replaced Dr. Powell as the IA Core Director. Due to steadily increasing demand for Core services, an additional half-time technician was hired in 2002. In January 2008, Scott Plevy replaced Michael Goy as IT Core Director. The strategic reason for this change was Dr. Plevy's expertise in cytokine biology and quantitative technologies, which historically has comprised the predominant usage of the core. In addition. Dr. Plevy brought new expertise in biomarker development and immune monitoring, which as described, will become new initiatives of the Core based on the prospective needs of CGIBD members. In April 2008, Carlton Anderson became the new IT Core Technician and Assistant Director. Mr. Anderson provides a wealth of laboratory experience and expertise. He has rapidly assimilated techniques for the most commonly requested ELISAs, has been trained on all existing equipment, and has developed, under the guidance of Dr. Plevy, new cost effective technologies for the Core. In parallel with these personnel changes, the objectives of the IT Core have also evolved and expanded. As the focus of the Center has shifted from diarrheal to inflammatory diseases and cancer, the needs of Center members have shifted and the IT Core has acquired new capabilities. From an initial repertoire of three immunoassays performed for a few investigators, the Core now serves a client base of over 50 laboratories, and offers a sophisticated array of services, including (a) over 50 different types of ELISA and RIA measurements, (b) custom immunoassay development, and (c) quantitative multiplex proteomic analysis that can be adapted to numerous applications. During the last funding cycle, as described elsewhere in this application, the proteomic component of the IT Core was eliminated. This decision reflects the existence of multiple cores on campus that provide cost-effective proteomic analysis, and followed polling and approval of CGIBD executive committee who concluded that such technology is no longer a high priority. To provide expanded and significantly more cost-effective services to the CGIBD community. Dr. Plevy initiated new cytokine ELISA development for the most requested cytokine assays based on established technology in CGIBD investigator's laboratories. Mr. Anderson has already negotiated better prices for standard ELISA kits;therefore, CGIBD investigators immediately benefitted by a 10-35% reduction in costs for services provided. With increased emphasis on translational research, the IT Core has embarked upon several new initiatives. An emphasis of the IT Core moving forward, facilitated by the acquisition of new technology platforms and thematically consistent with the NIH Roadmap, will be biomarker development with an emphasis on human studies. We are now performing multiplex protein analysis using xMAP technology. We have negotiated with Bio-Rad and R and D Systems to receive discounted prices on multiplex kits for the Core's Bio-Plex 200 system which will facilitate human and murine research, and contribute to biomarker development. Additionally, we are planning an on-site symposium to better acquaint investigators with the multiplex platform. We have also established collaboration with Glycominds, Inc. to develop ELISA-based serological markers directed against the enteric microbiota in human inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and inflammatory liver diseases. Finally, as a result of recent NIH funded and industry sponsored activities of several Center investigators, the Core has taken an interest in immune monitoring in IBD patients, including but not limited to, immunogenicity and vaccine monitoring, and immunocompetence and reconstitution during therapeutic interventions. Development of this technology will be applicable across many GI disorders where assessing subtle effects on the human immune system will be critical to understand safety and efficacy of clinical interventions, including trials of vaccinations, cellular therapy, drug therapy, cancer immunotherapy, transplantation, and autoimmune/inflammatory disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK034987-27
Application #
8374541
Study Section
Special Emphasis Panel (ZDK1-GRB-8)
Project Start
Project End
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
27
Fiscal Year
2012
Total Cost
$132,411
Indirect Cost
$42,661
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Livraghi-Butrico, A; Grubb, B R; Wilkinson, K J et al. (2016) Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. Mucosal Immunol :
Chung, Arlene E; Sandler, Robert S; Long, Millie D et al. (2016) Harnessing person-generated health data to accelerate patient-centered outcomes research: the Crohn's and Colitis Foundation of America PCORnet Patient Powered Research Network (CCFA Partners). J Am Med Inform Assoc 23:485-90
Medina, Eduardo; Pérez-Díaz, Ilenys M; Breidt, Fred et al. (2016) Bacterial Ecology of Fermented Cucumber Rising pH Spoilage as Determined by Nonculture-Based Methods. J Food Sci 81:M121-9
Johnson, Amy R; Qin, Yuanyuan; Cozzo, Alyssa J et al. (2016) Metabolic reprogramming through fatty acid transport protein 1 (FATP1) regulates macrophage inflammatory potential and adipose inflammation. Mol Metab 5:506-26
Kang, Dae Joong; Betrapally, Naga S; Ghosh, Siddhartha A et al. (2016) Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. Hepatology 64:1232-48
Asher, Gary N; Xie, Ying; Moaddel, Ruin et al. (2016) Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers. J Clin Pharmacol :
Dellon, Evan S; Cotton, Cary C; Gebhart, Jessica H et al. (2016) Accuracy of the Eosinophilic Esophagitis Endoscopic Reference Score in Diagnosis and Determining Response to Treatment. Clin Gastroenterol Hepatol 14:31-9
Kochar, Bharati; Aldridge, Molly; Cook, Suzanne Follan et al. (2016) Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease. J Med Internet Res 18:e124
Henning, Susan J; von Furstenberg, Richard J (2016) GI stem cells - new insights into roles in physiology and pathophysiology. J Physiol 594:4769-79
Lewis, Cari M; Wolf, W Asher; Xun, Pengcheng et al. (2016) Racial differences in dietary changes and quality of life after a colorectal cancer diagnosis: a follow-up of the Study of Outcomes in Colorectal Cancer Survivors cohort. Am J Clin Nutr 103:1523-30

Showing the most recent 10 out of 826 publications